金吾财讯 | 英派药业-B（07630）盘中逆市拉升40.06%，暂报18.25港元，成交额3.25亿港元。消息面上，该公司发布公告，欧洲药品管理局（EMA）人用药品委员会（CHMP）已通过了一项积极意见，建议批准药品Sepalna（塞纳帕利）的上市许可（MA），该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会（EC）作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。据悉，英派药业与Pharmanovia于2026年7月达成独家合作，英派药业授予Pharmanovia在66个国家（包括全部27个欧盟成员国，以及英国、挪威、冰岛、瑞士、列支敦士登、澳洲、新西兰及中东和北非地区国家）制造、开发及商业化塞纳帕利的独家权利，用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌的维持单药治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.